(PubMed) Qin X, Xu M, Zhang Y, et al
Insights Imaging 15 , 282 (2024)
Loading phase protocol (acute injury or initial treatment): Dose: 500 mcg to 1 mg per injection Frequency: Once daily Duration: 7 to 10 days Injection site: Subcutaneous, ideally near the area of concern Timing: Morning or evening, consistency matters more than specific time Maintenance phase protocol: Dose: 500 mcg to 1 mg per injection Frequency: 2 to 3 times per week Duration: 4 to 8 weeks total protocol length Cycle recommendation: 2 months on, 2 months off Unlike traditional BPC-157 acetate, which is often administered twice daily due to its shorter half-life, the enhanced stability of the arginate form typically allows for once-daily dosing during the loading phase
Moderate alcohol consumption, defined as up to one drink per day for women and up to two drinks per day for men, is generally considered acceptable for most patients, though individual tolerance and circumstances should be considered
Half-measures and partial implementations are unlikely to achieve meaningful reductions in diagnostic delays
